Reports Q4 revenue $1.63M, consensus $50,000. Reports Q4 research and development expenses $82.1M as compared to $30.5M during the Q4 of 2022.As of December 31, 2023, Inhibrx had cash and cash equivalents of $277.9M, compared to $337.3M as of September 30, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INBX:
- Inhibrx Announces Execution of Merger Agreement
- Inhibrx Announces Merger and Spin-Off Agreements with Aventis
- Inhibrx downgraded to Market Perform from Outperform at LifeSci Capital
- M&A News: Sanofi Expands into Rare Diseases with Inhibrx Deal
- Inhibrx to sell INBRX-101 to Sanofi in $2.2B transaction
